GW Henssler & Associates’s Bristol-Myers Squibb BMY Stock Holding History

GW Henssler & Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-4,934	Closed	-$256K	–	143
2014 Q1	$256K	Buy	4,934 +80	+2%	+$4.26K	0.03%	141
2013 Q4	$258K	Buy	4,854 +117	+2%	+$5.96K	0.03%	138
2013 Q3	$220K	Buy	4,737 +6	+0.1%	+$263	0.03%	142
2013 Q2	$211K	Buy	+4,731	New	+$205K	0.03%	137

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

GW Henssler & Associates's BMY Position: Q2 2014 in Review

GW Henssler & Associates sold out of Bristol-Myers Squibb (BMY) in Q2 2014, closing a stake of 4,934 shares — an estimated $256K sold.

GW Henssler & Associates first reported a position in BMY in Q2 2013 and held it in 4 quarters. The position peaked at $258K in Q4 2013. 1,302 funds tracked by Wall St. Rank hold BMY as of Q2 2014.

GW Henssler & Associates reported no remaining Bristol-Myers Squibb position as of Q2 2014 after selling out during the quarter.
GW Henssler & Associates sold 4,934 Bristol-Myers Squibb shares in Q2 2014, an estimated $256K.
GW Henssler & Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 4 quarters.
GW Henssler & Associates's Bristol-Myers Squibb position peaked at $258K in Q4 2013.
1,302 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2014.

Based on GW Henssler & Associates's 13F filing for Q2 2014, filed 12 Aug 2014.